Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: stabilanol is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. stabilanol can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence.therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.consideration should be given to official guidance on the appropriate use of antifungals.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluconazole - solution for infusion - fluconazole 2 mg/ml - fluconazole - fluconazole - stabilanol is indicated in the following fungal infections .stabilanol is indicated in adults for the treatment of: • cryptococcal meningitis .• coccidioidomycosis. invasive candidiasis.• mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis.• chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.stabilanol is indicated in adults for the prophylaxis of: • relapse of crytopcoccal meningitis in patients with high risk of recurrence.• relapse of oropharyngeal or oesophageal candidiasis in patients infected with hiv who are at high risk of experiencing relapse.• prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving hematopoietic stem cell transplantation ).stabilanol is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old: sta

European Union - English - EMA (European Medicines Agency)

avimedical b.v. - itraconazole - antimycotics for systemic use, triazole derivatives, itraconazole - avian - for the treatment of aspergillosis and candidiasis in companion birds,

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - caspofungin acetate, quantity: 77.7 mg - injection, powder for - excipient ingredients: mannitol; sucrose; sodium hydroxide; hydrochloric acid - caspofungin an is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - caspofungin acetate, quantity: 55.5 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sodium hydroxide; sucrose; hydrochloric acid; mannitol - caspofungin an is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: hypromellose acetate succinate; microcrystalline cellulose; hyprolose; silicon dioxide; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - noxafil (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older; invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy; fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. prophylaxis of invasive fungal infections, among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; magnesium stearate; lactose monohydrate; maize starch; silicon dioxide; titanium dioxide; potable water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - for vaginal candidiasis

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - fluconazole, quantity: 150 mg - capsule, hard - excipient ingredients: titanium dioxide; maize starch; sodium lauryl sulfate; colloidal anhydrous silica; patent blue v; lactose monohydrate; gelatin; purified talc - treatment of vaginal candidiasis.